Passage Bio Investor Relations Material
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The Company's lead products in clinical development are TB-403, a novel oligonucleotide modulator of thromboxane receptors (TXRs) and P7C3, a small molecule oral GPCR modulator that targets the vasoactive intestinal peptide (VIP). The company has a bold vision to fulfill the promise of gene therapy by delivering medicines that provide a cure for previously incurable diseases
Key slides for Passage Bio Inc
Marvel-ous Reporting: Marvel’s Comic Inspired Reports
Shareholder reports are often considered tedious and dry. However, in the late 1980s and early 1990s, Marvel Comics revolutionized this perception by transforming its financial reports into captivating comic books.
8 Dec 2023
The Payments Value Chain: A Complex Ecosystem
The payments industry is a complex and dynamic field involving multiple key players. These include customers, merchants, issuers, acquirers, card networks, and various other entities together forming the payments value chain.
8 Dec 2023
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
🇺🇸 United States